TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Enucleation efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Mean Change in A1C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gut inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: motor fatigability
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Trait motor fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Post operative morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving HbA1c level of less than 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Free From Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Requirement for analgesic and antibiotic medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline ACQ-5 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best Anatomical Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Adverse events in terms of changes in Hematology
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse events in terms of changes in Urinalysis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse events in terms of changes in Biochemistry (fasting)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse events in terms of changes in Physical examinations
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adverse events in terms of changes in Vital signs
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 to Time t [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time 0 Extrapolated to Infinity [AUC(0-∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive Protein (CRP) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of lucanthone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local-regional recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time to defecate and tolerate for food
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: efficacy of doxycycline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of doxycycline in combination with MTX
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Favorable Modified Rankin Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Severe Hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ocular symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum contact pressure for spectroscopic measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change in Bone Mineral Density (BMD) T-Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean 24 hour ambulatory systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motilin hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Gastrin hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Secretin hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cholecystokinin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: overall severity score from the Clinical Global Impressions assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Harris hip scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood TNF-alpha rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: POGO score for direct laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: POGO score for TrachView™
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb function as measured by the Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of the allergic rhinitis control self questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in fat layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Persons repeating a suicidal act
Endpoint domain: Mortality/survival
Primary endpoint: Randomization Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: focal lesion detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early diagnosis of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to Swallowing Exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Coefficient of variation of levodopa in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment - Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of B cell subpopulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of IL 10 in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Glycated hemoglobin (A1c) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes medical error
Endpoint domain: Adverse events/effects
Primary endpoint: Teacher's rating of student's transformational leadership
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Gastric emptying at 2 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Children Born With Major Birth Defects
Endpoint domain: Mortality/survival
Primary endpoint: Change in Perianal disease activity index (PDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life related to activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall success rate of IV placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with positive humoral immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in muscle phospho-proteome signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Disease Activity Score (DAS28-ESR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention of Participants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean Number of Adverse Events Following Each Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Halflife of Theophylline (Aminophylline) and Ambrisentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Until Maximum Plasma Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Within 24 Hours Post Dosing (AUC_0-24 Hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanisms of resistance of myeloma cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of Appendiceal Enterobius vermicularis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Back related function (Modified Roland Morris Disability Scale)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Side effects during cerebrolysin therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of vaccine-related adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of vaccine against anti-Langat neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of hepatitis B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of hepatitis C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of hyperlipidemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tumor localization accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Non-serious Adverse Event (AE), Serious Adverse Event (SAE), or Drug-related Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Counts of White Blood Cells (WBC), Total Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, and Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adjusted Median Response of Cytokine Concentrations in Induced Sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Antiplatelet medications used during hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of bleeding events during hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of peri-implantitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of false visual perceptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight & anthropometric measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to diets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Mean Weekly CSBMs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensory attributes of drug product formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Adverse Events (AEs) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Serum Concentration (Cmax) of Daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Trough Concentration (Ctrough) of Daratumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: National Institutes of Health Stroke Severity (NIHSS) Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Total Exercise duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedural Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events attributed to CAR-T cell administration
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With 25% Reduction in SNAP Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants positive for influenza A by iTreat Flu A+B Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants positive for influenza A by ellume.lab Flu A+B Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants negative for influenza A by iTreat Flu A+B Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants negative for influenza A by ellume.lab Flu A+B Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of participants positive for influenza B by iTreat Flu A+B Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With Nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Bloating
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Constipation
Endpoint domain: Adverse events/effects
Primary endpoint: Body weight in kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index in Kg/m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of post inflammatory hyperpigmentation
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients transfused with homologous red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Final Fractional Flow Reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Clinical Remission Per Crohn's Disease Activity Index (CDAI) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinical Remission Per Patient-Reported Outcomes (PROs) at Week 12
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With Endoscopic Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Symptom Severity Scale (BSSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Functional Capacity Scale (BFCS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of Eyelid retraction grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic yield of pancreatic solid lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Meter Time Up and Go (6TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of volitional movement of lower limbs using electromyographic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trunk stability measurement (trunk control assessment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VQ11 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: radiological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive SFLT-1 / PLGF ratio cat-off point for preeclampsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Neuropathic Pain Qualities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in platelet aggregation AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in Estimated Ultrasensitive Plasma HIV RNA Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in traumatic acute pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CWS Removal From Birth Parent Home
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Parental Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Secure Base Behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence rate of access to renal transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Inhibition of receptor auto-phosphorylation in HER-2 amplified patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of receptor auto-phosphorylation in HER-1 and HER-2 co-expressing patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Effect Curve for Absolute Neutrophil Count (AUECANC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Duration of Severe Neutropenia (DSN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of Vardenafil treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Vardenafil treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerance of Vardenafil treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Appearance of Type 1 Diabetes Associated Auto-antibodies in Serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Early Preterm Birth (<34 weeks gestation)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Patient Knowledge about Diabetes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Treatment-related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Urine volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cmax of edaravone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of edaravone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ of edaravone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-related potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaccine induced binding antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine induced neutralizing antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of the late boost vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in team cohesion
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in molecular biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Pain Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of contact precautions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Age of thrombus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rejection-related diagnoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MI (myocardial infarction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with clinically significant changes in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinically significant changes in 12-lead ECG (Electrocardiogram)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in exaggerated postprandial lipemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Lipotest meal values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Vascular Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Energy Expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Postoperative Delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Total Polys Score (TPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norepinephrine transporter (NET) ligand concentrations at Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: norepinephrine transporter (NET) ligand concentrations in hyperinsulinemic-hypoglycemic Condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vitamin D serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes